Clinical Trials Logo

Encephalopathy, Hepatic clinical trials

View clinical trials related to Encephalopathy, Hepatic.

Filter by:
  • None
  • Page 1

NCT ID: NCT02464124 Recruiting - Clinical trials for Encephalopathy, Hepatic

Nitazoxanide Plus Lactulose Versus Lactulose Alone Treatment of Hepatic Encephalopathy

Start date: January 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Hepatic encephalopathy (HE) is a reversible neuropsychiatric syndrome associated with chronic and acute liver dysfunction. It is characterized by cognitive and motor deficits of varying severity. Treatment options include lactulose administered orally or by nasogastric tube or enema, non-absorbable antibiotics, and protein-restricted diets. Nitazoxanide is an oral agent indicated for the treatment of infectious diarrhea caused by Crytpsporidiumparvum and Giardia lamblia. Basu and colleagues presented a pilot prospective study at the 2008 American Association for the Study of Liver Diseases meeting showing clinical improvement in HE among cirrhotic patients who received nitazoxanide and lactulose.

NCT ID: NCT01597102 Recruiting - Clinical trials for Cerebrovascular Disorders

Cerebrovascular Autoregulation During and After Liver Transplantation

dARICULtx
Start date: January 8, 2012
Phase:
Study type: Observational

The cerebrovascular autoregulation (AR) is impaired in patients with hepatic encephalopathy. Patients with the indication to liver transplantation mostly have mild to severe hepatic encephalopathy. Transplantation should recover the encephalopathy. The aim of the study is to investigate the AR during liver transplantation, with the questions if the AR is impaired at the beginning of surgery and if there are changes in AR. For follow up the AR will be measured at the first days after transplantation at the ICU.

NCT ID: NCT00553423 Recruiting - Clinical trials for Encephalopathy, Hepatic

Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage

Start date: November 2007
Phase: Phase 3
Study type: Interventional

To evaluate the role of lactulose in prevention of clinically overt hepatic encephalopathy (HE) in the setting of acute upper gastrointestinal bleeding in cirrhotic patients